Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BETOPTIC S · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Betaxolol | EXPERIMENTAL | Two doses daily for 12 weeks |
| TGFS 0.25% | EXPERIMENTAL | Two doses daily for 12 weeks |
| TGFS 0.5% | EXPERIMENTAL | Two doses daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| BETOPTIC S (betaxolol HCl) | DRUG | betaxolol HC) |
| Timolol Gel-forming Solution (TGFS) | DRUG | timolol maleate 0.25% and 0.5% |
INCLUSION: * Children 5 years old and younger * require treatment for glaucoma or ocular hypertension * whose vision is 20/80 or better * have a cup-to-disc ratio of 0.8 or less EXCLUSION: * do not have abnormal fixation * IOP greater than 36 mm Hg * significant retinal disease * penetrating kera...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
BETOPTIC S is a small molecule used for the treatment of glaucoma. It is being developed by Alcon Inc. for use in ophthalmology. The drug is currently in Phase 3 clinical development for this indication.
BETOPTIC S is a small molecule used for glaucoma. Its specific molecular target is not disclosed in the available information. The drug is being developed by Alcon Inc. and is in Phase 3 clinical trials.
BETOPTIC S is developed by Alcon Inc., a company traded under the ticker ALC. The drug is a small molecule in Phase 3 clinical development for the treatment of glaucoma.
BETOPTIC S is in Phase 3 clinical development. It is an investigational drug for the treatment of glaucoma and has not been approved by regulatory authorities. The drug is being developed by Alcon Inc.
BETOPTIC S has one completed Phase 3 clinical trial, NCT00061542, which studied the safety and efficacy of BETOPTIC S 0.25% compared with Timolol Gel-forming Solution in pediatric patients with glaucoma or ocular hypertension. The trial enrolled 105 participants in the United States.
No, BETOPTIC S is not the same as Timolol. BETOPTIC S is a separate drug being developed by Alcon Inc. for glaucoma. In clinical trial NCT00061542, BETOPTIC S 0.25% was studied against Timolol Gel-forming Solution as a comparator.